MedTrace Logo

Combination of SABR and L19-IL2 in Patients With Stage IV Lung Cancer (ImmunoSABR)

NCT02735850 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2017-05-23

No results posted yet for this study

Summary

This will be a phase II trial testing if the combination of SBRT and L19-IL2 improves the progression free survival in patients with limited metastatic non-small cell lung cancer (NSCLC). Treatment will be divided in two cohorts: patients eligible for ablative stereotactic body radiotherapy to all metastatic sites (treatment with curative intent) and patients not eligible for stereotactic body radiotherapy to all sites (life prolongation).

Conditions

  • NSCLC Stage IV
  • Limited Metastatic Disease

Interventions

DRUG

L19-IL2

L19-IL2 added to SBRT

RADIATION

SBRT

OTHER

No intervention

Sponsors & Collaborators

  • Maastricht University Medical Center

    collaborator OTHER

  • Karolinska Institutet

    collaborator OTHER

  • University of Oxford

    collaborator OTHER

  • KU Leuven

    collaborator OTHER

  • Copenhagen University Hospital at Herlev

    collaborator OTHER

  • Catholic University of the Sacred Heart

    collaborator OTHER

  • The Netherlands Cancer Institute

    collaborator OTHER

  • Maastricht Radiation Oncology

    lead OTHER

Principal Investigators

  • Philippe Lambin, MD, PhD · Maastro Clinic, The Netherlands

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-12-31
Primary Completion
2021-02-28
Completion
2021-06-30

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02735850 on ClinicalTrials.gov